September 20, 2023 News by Andrea Lobo, PhD Patient enrollment is complete in Phase 1 trial of ANK-700 for RRMS Anokion has finished enrolling patients in the second part of its Phase 1 clinical trial investigating ANK-700 for relapsing-remitting multiple sclerosis (RRMS). Safety data so far from the MoveS-it trial (NCT04602390) has shown the treatment is safe and well tolerated and biomarker analyses suggest it can induce…
January 7, 2022 News by Yedida Y Bogachkov PhD Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses A Phase 1 clinical trial investigating the safety and tolerability ofĀ Anokion‘s ANK-700 in people withĀ relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening of the study’s second part follows positive safety signs in patients given the one of two doses of…
March 25, 2021 News by Diana Campelo Delgado Dosing Begins in Trial of Anokion’s ANK-700 for RRMS A Phase 1 clinical trial investigating ANK-700 as a means to restore immune tolerance to myelin in people multiple sclerosis (MS) has begun dosing participants. Currently recruiting at a single site in Tennessee, the trial (NCT04602390) is expected to enroll up to 40 patients with relapsing-remitting…
March 4, 2021 News by Margarida Maia, PhD Antigen-loaded Red Blood Cells Help Promote Immune Tolerance in Mice Red blood cells carrying specific antigen proteins on the cell surface can be used to disarm overactive T-cells by promoting immune tolerance, a study in mice found. The findings may have important implications for the treatment of autoimmune diseases like multiple sclerosis. The study, āPersistent antigen…
September 28, 2020 Columns by Ed Tobias MS News That Caught My Eye Last Week: Global MS Numbers, Pregnancy and MS, ANK-700 MS Prevalence at Over 2.8 Million Worldwide, Update to Atlas Reports With almost 3 million of us around the world, we’re not really rare, but we’re rare enough that our MS is still a puzzle to many. People seem to know what muscular dystrophy is (probably because of the…
September 25, 2020 News by Marisa Wexler, MS Anokion Planning Launch of Phase 1 Trial of Investigational MS Therapy ANK-700 The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700, a treatment candidate for multiple sclerosis (MS) that is being developed by the Swiss company Anokion. With this approval, Anokion can enter clinical testing and is planning to…